Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for PONV in High Risk Patients
NCT02357693Phase 4Completed
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Aprepitant Group with Placebo Group (2 arms). Primary endpoint: Incidence of nausea and vomiting in postoperative period at 24 hours. Started Feb 2015; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT02357693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357693.